AIM: To evaluate the safety and long-term efficacy of intravitreal bevacizumab injection(IVB)as therapy for chronic central serous chorioretinopathy(CSC).

METHODS: Six patients(6 eyes)with CSC were treated with an intravitreal injection of bevacizumab(1.25mg/0.05mL). 5 patients received second intravitreal injection of bevacizumab 3 months after the first injection. Patients had follow-up on 1, 3, 6, 12, 24 months after the injections. Outcome measures included pre and post-treatment changes in best-corrected visual acuity, intraocular pressure(IOP), subretinal fluid(SRF)measurement with optical coherence tomography(OCT), changes in fluorescein angiography(FA).

RESULTS: After the first injection, 1 patient showed resolution of SRF completely, while his visual acuity showed no change; 1 patient whose visual acuity improved and SRF resolved completely on 1 month recurred; 3 patients showed no obvious changes in the SRF and in visual acuity; 1 patient showed decreased thickness of SRF while his visual acuity were stable. After the second injection, 1 patient showed resolution of SRF completely with improved his visual acuity; 2 patients showed resolution of SRF completely, while his visual acuity showed no change; the others showed no obvious change. The changes of SRF and visual acuity seemed to have no direct relation. The visual acuity showed no significant difference before and 12,24 months after the first injections. Pre and post-treatment the IOP of the 6 patients all belong to normal range. No cases of endophthalmitis were reported.

CONCLUSION:IVB have some effect in chronic CSC cases in improving subretinal fluid resolution. But IVB have no long-term effect on improving visual acuity.